PharmaCyte Biotech (PMCB) Other Non-Current Assets (2013 - 2026)
PharmaCyte Biotech (PMCB) posted quarterly Other Non-Current Assets of $7688.0 for Q2 2026, little changed year-over-year from $7688.0 in Q2 2025, and little changed quarter-over-quarter from $7688.0 in Q1 2026.
PharmaCyte Biotech (PMCB) Other Non-Current Assets (2013 - 2026) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Other Non-Current Assets for 14 consecutive years, with $7688.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Other Non-Current Assets changed 0.0% year-over-year to $7688.0; the TTM figure through Apr 2026 stood at $7688.0 (changed 0.0% YoY), while the FY2026 annual figure was $7688.0, changed 0.0% from the prior year.
- Other Non-Current Assets steadied at $7688.0 in Q2 2026 per PMCB's latest filing, from $7688.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $2.0 million in Q1 2024 and bottomed at $7688.0 in Q1 2022.
- Historically, Other Non-Current Assets has averaged $119038.7 across 5 years, with a median of $7688.0 in 2022.
- Annual changes were most pronounced in 2024 — Other Non-Current Assets soared 26070.66% — and 2025, when it sank 99.62%.
- PharmaCyte Biotech's Other Non-Current Assets stood at $7688.0 in 2022, then changed by 0.0% to $7688.0 in 2023, then changed by 0.0% to $7688.0 in 2024, then changed by 0.0% to $7688.0 in 2025, then changed by 0.0% to $7688.0 in 2026.
- Business Quant data shows PMCB's Other Non-Current Assets at $7688.0 in Q2 2026, $7688.0 in Q1 2026, and $7688.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | PharmaCyte Biotech | 4.38 Mn | 4.38 Mn | - | 7,688.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 7,688.00 |
| Jan 31, 2026 | 7,688.00 |
| Oct 31, 2025 | 7,688.00 |
| Jul 31, 2025 | 7,688.00 |
| Apr 30, 2025 | 7,688.00 |
| Jan 31, 2025 | 7,688.00 |
| Oct 31, 2024 | 7,688.00 |
| Jul 31, 2024 | 7,688.00 |
| Apr 30, 2024 | 7,688.00 |
| Jan 31, 2024 | 2.01 Mn |
| Oct 31, 2023 | 7,688.00 |
| Jul 31, 2023 | 7,688.00 |
| Apr 30, 2023 | 7,688.00 |
| Jan 31, 2023 | 7,688.00 |
| Oct 31, 2022 | 7,688.00 |
| Jul 31, 2022 | 7,688.00 |
| Apr 30, 2022 | 7,688.00 |
| Jan 31, 2022 | 7,688.00 |
| Oct 31, 2021 | 7,688.00 |
| Jul 31, 2021 | 7,372.00 |